Molecular prognostic and predictive markers in colorectal cancer: Current status

Current Colorectal Cancer Reports

Volumn 7, Issue 2, 2011, Pages 136-144

  Lee, Jeffrey K ^a   Chan, Andrew T ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarkers; Chemotherapy; Colorectal cancer; Markers; Predictive; Prognostic; Targeted therapies

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; APC PROTEIN; B RAF KINASE; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID SYNTHASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PHARMACOLOGICAL BIOMARKER; PROTEIN P53; THYMIDYLATE SYNTHASE; VASCULOTROPIN;

ADENOMATOUS POLYP; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; CLINICAL TRIAL (TOPIC); COLON CANCER; COLON MUCOSA; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA METHYLATION; DRUG TARGETING; ENZYME ACTIVITY; FAMILIAL DISEASE; GENE INACTIVATION; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INTESTINE EPITHELIUM; LONG INTERSPERSED REPEAT; MISMATCH REPAIR; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 80051794463     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-011-0091-4     Document Type: Review

References (51)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-5. (Pubitemid 39429665)
3. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSCIA trial. J Clin Oncol. 2009;27:3109-16.
4. Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist. 2006;11:981-7. (Pubitemid 44564805)
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
6. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.
7. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95. (Pubitemid 32225406)
8. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-32.
9. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135:1079-1099.
10. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-57. (Pubitemid 36859476)
11. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-18. (Pubitemid 46224239)
12. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETAC 3-EORTC 40993-SAKK60/00 trial). J Clin Oncol. 2009;27:15s. [Abstract: 4001]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29-June 2, 2009.
13. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracilbased adjuvant therapy in colon cancer. J Clin Oncol 2010; 28:3219-26.
14. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol. 2009;27:1814-21.
15. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89802. Clin Cancer Res. 2009;15:7322-9.
16. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675-84. (Pubitemid 28222141)
17. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer. 2001;85:692-6. (Pubitemid 32929467)
18. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 6000 trial. J Clin Oncol. 2010;28:466-74.
19. Amado RG, Wolf M, Peters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34.
20. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Biomarkers predictive for outcome on patients with metastatic colorectal cancer treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study [Abstract: 428]. Presented at the 2010 Gastrointestinal Cancers Symposium. Orlando, Florida; January 22-24, 2010
21. Kohne C, Stroiakovski D, Chang-chien C, et al. Predictive biomarkers to improve treatment of metastatic colorectal cancer; outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol. 2009;27:15s. [Abstract: 4068]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29-June 2, 2009.
22. Van Cutsem E, Rougier P, Kohne C, et al. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy as 1st line treatment for patients with metastatic colorectal cancer: results according to KRAS and BRAF mutation status. Eur J Cancer. 2009;7:324. [Abstract: 6077]. Presented at the 2009 ECCO/ESMO Multidisciplinary Congress Meeting. Berlin, Germany; September 20-24, 2009.
23. Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumorigenesis. J Pathol. 2007;212:124-33. (Pubitemid 46852090)
24. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res. 2005;65:6063-9.
25. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatelite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;5858:90-6.
26. Van Cutsem E, Lang G, Folprecht M, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol. 2010;28:15s. [Abstract: 3570]. Presented at the 2010 Annual Meeting of the ASCO. Chicago, Illinois; June 4-8, 2010.
27. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer. 2005;41:2060-70. (Pubitemid 41337947)
28. Sun XF, Rutten S, Zhang H, et al. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol. 1999;17:1745-50. (Pubitemid 29269243)
29. Watanabe T, Wu TT, Catalano PL, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196-206. (Pubitemid 32319494)
30. Bertagnolli MM, Niedzwiecki D, Hall M, et al. Presence of 18q loss of heterozygosity (LOH) and disease free and overall survival in stage II colon cancer: CALGB Protocol 89803. J Clin Oncol. 2009;27:15s. [Abstract: 4012]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29-June 2, 2009.
31. Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutations: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518-28. (Pubitemid 46291815)
32. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol. 2003;21:241-50. (Pubitemid 46606152)
33. Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23:5635-43.
34. Popat S, Chen Z, Zhao D, et al. A prospective, blinded analysis of thymidylate synthase and p53 expression a prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol. 2006;17:1810-7. (Pubitemid 44884057)
35. Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol. 2002;20:1721-8. (Pubitemid 34273259)
36. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529-36. (Pubitemid 41079782)
37. Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2009;19:915-9. (Pubitemid 351627307)
38. Johnston G, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994;12:2640-7. (Pubitemid 24379651)
39. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. Postgrad Med J. 2008;84:403-11.
40. El-Khoueiry A, Pohl A, Danenberg K, et al. Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients with metastatic colorectal cancer treated with first line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol. 2009;27:15s. [Abstract: 4056]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29-June 2, 2009.
41. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10:8465-71. (Pubitemid 40053411)
42. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxygenase-2 is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221-7.
43. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649-58.
44. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734-8.
45. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology. 2010;138:2029-43.
46. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26:5713-20.
47. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004;22:1564-71. (Pubitemid 41079793)
48. Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958-68.
49. O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937-44.
50. Tomlinson IP, Webb E, Carvajal-Carmona L. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosome 10p14 and 8q23.3. Nat Genet. 2008;40:623-30. (Pubitemid 351601204)
51. Tenesa A, Theodoratou E, Din FV, et al. Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. Clin Cancer Res. 2010;16:3754-9.